Prolactin secretion disturbances in schizophrenic patients treated with 2nd generation antipsychotics - Risperidone and olanzapine;Zaburzenia wydzielania prolaktyny u chorych na schizofreniȩ leczonych lekami przeciwpsychotycznymi II generacji - Risperidonem i olanzapina̧

Psychiatria Polska

Volumn 39, Issue 6, 2005, Pages 1143-1155

  Wyszogrodzka Kucharska, Anna ^a,c   Kunert Radek, Jolanta ^b   Rabe Jabłonska, Jolanta ^c  

^a Centralny Szpital Kliniczny   (Poland)

^b Klinika Endokrynologii   (Poland)

^c NONE   (Poland)

Author keywords

Antipsychotic therapy; Hyperprolactinemia; Schizophrenia

Indexed keywords

OLANZAPINE; PROLACTIN; RISPERIDONE;

ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG SAFETY; FEMALE; HUMAN; HYPERPROLACTINEMIA; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOPAMINE; FEMALE; HUMANS; HYPERPROLACTINEMIA; MALE; METOCLOPRAMIDE; MIDDLE AGED; PREVALENCE; PROLACTIN; RISPERIDONE; SCHIZOPHRENIA;

EID: 31044456555     PISSN: 00332674     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Mah PM, Webster J. Hyperprolactinemia: etiology, diagnosis and managment. Semin. Reprod. Med. 2002; 20: 365-373.
2. Keks NA, Copolov DL, Kulkarni J, Mackie B, Singh BS, Mc Gorry P, Rubin RT, Hasset A, Mc Laughlin M, van Riel R. Basal and haloperidol-stimulated prolactin in neuroleptic-free men with schizophrenia. Biol. Psychiatry 1990; 27: 1203-1215.
3. Rubin RT. Prolactin and schizophrenia. Psychopharmacology: The third generation of progress. New York: Raven Press; 1987, s. 803-808.
4. Kinon BJ, Gilmore JA, Liu H, Halbriech U. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications and risperidone. Psychoneuroendocrinol. 2003; 28: 55-68.
5. Markianos M, Hatzimanolis J, Lykouras L. Gonadal axis hormones in male schizophrenic patients during treatment with haloperidol and after switch to risperidone. Psychopharmacol. 1999; 143: 270-272.
6. Kearns AE, Goff DC, Hayden DL, Daniels GH. Risperidone associated hyperprolactinemia. Endocr. Pract. 2000; 6: 425-429.
7. David SR, Taylor CC, Kinon B, Breier A. The effects of olanzapine, risperidone and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin. Therapeutics 2000; 22, 9: 1085-1096.
8. Brunelleschi S, Zeppegno P, Risso F, Cattaneo CI, Torre E. Risperidone-associated hyperprolactinemia: evaluation in twenty psychiatric outpatients. Pharmacol. Res. 2003; 48: 405-409.
9. Beasley CM Jr., Hamilton SH, Crawford AM, Dellva MA, Tollefson GD, Tran PW, Blin O, Beuzen JN. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur. Neuropsychopharmacol. 1997; 7(2): 125-137.
10. Crawford AMK, Beasley CM. Jr., Tollefson GD. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr. Res. 1997; 26: 41-54.
11. Kinon BJ, Gilmore JA, Liu H, Halbriech U. Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative trials. Psychoneuroendocrinol. 2003; 8: 69-82.
12. Tollefson GD, Beasley CM Jr., Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME. Olanzapine versus haloperidol in the treatment of schizophrenia, schizoaffective and schizophreniform disorders: results of an internatinal collaborative trial. Am. J. Psychiatry 1997; 154: 457-465.
13. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beaslej CM Jr., Tollefson G. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J. Clin. Psychopharmacol. 1997; 17: 407-418.
14. Karagianis JL. High dose olanzapine and prolactin levels. J. Clin. Psychiatry 2003; 64(10): 1192-1194.
15. Klibanski A, Neer RM, Beitins IZ, Ridgway EC, Zervas NT, Mc Arthur JW. Decreased bone density in hyperprolactinemic women. N. Engl. J. Med. 1980; 173(26): 1511-1514.
16. Klibanski A, Biller BMK, Rosenthal DI, Schoenfeld DA, Saxe V. Effect of prolactin and estrogen deficiency in amenorrheic bone loss. J. Clin. Endocrinol. Metab. 1988; 67: 118-117.
17. Buvat J, Lemaire A. Hyperprolactinemia and sexual function in men. Hormone Res. 1985; 22: 196-203.
18. Dickson RA, Dalby JT, Williams R, Edwards AL. Risperidone-induced prolactin elevations in premenopausal women with schizophrenia (letter). Am. J. Psychiatry 1995; 152: 1102-1103.
19. Kleinberg D, Davis JD, Coster R, Van Baelen B, Brecher M. Prolactin levels and adverse events in patients treated with risperidone. J. Clin. Psychopharmacol. 1999; 19 (1): 57-61.
20. Kaneda Y, Fuji A, Yamaoka T, Morimoto T. Neither gynecomastia nor galactorrhea is a common side effect of neuroleptics in male patients. Neuroendocrinol. Lett. 2000; 21: 447-451.